By Associate Professor Yeh Chen Lee

Journal articles

Lee CK; Kartikasari AER; Bound NT; Francis KE; Shield-Artin K; Bedo J; Nesic K; Diamante K; O’Connell RL; Madondo M; Cox M; Davies C; Deceneux C; Goodchild G; Jarratt A; Cassar E; Amer H; Kariyawasam UGIU; Lee YC; Lombard J; Baron-Hay S; Antill Y; Shannon C; Selva-Nayagam S; Beale P; Zebic D; Simon S; Linaker A; Quinn MA; Papenfuss AT; Wakefield MJ; Vandenberg CJ; Friedlander M; Scott CL; Plebanski M, 2025, 'Olaparib, durvalumab, and cyclophosphamide, and a prognostic blood signature in platinum-sensitive ovarian cancer: the randomized phase 2 SOLACE2 trial', Nature Communications, 16, http://dx.doi.org/10.1038/s41467-025-64130-6

Noh A; Thompson SR; Lehane C; Parasyn A; Lee YC; Crowe P; Ho Shon I, 2025, 'Fluoro-2-deoxy-d-glucose PET radiomic analysis predicts outcome in patients with soft tissue sarcoma.', Nucl Med Commun, http://dx.doi.org/10.1097/MNM.0000000000002074

Garg V; Armstrong E; Celeste A; Wang C; Shukla A; Tesfu A; Odujoko O; Madariaga A; Lee YC; Wang L; Alqaisi H; Soberanis P; Grant B; Braik D; Chawla T; Shlomovitz E; Veneziani A; Dhani N; Grant R; Jivraj N; Bowering V; Oza AM; Allard JP; Coburn B; Lheureux S, 2025, 'Multidisciplinary ambulatory management of malignant bowel obstruction (MAMBO) program in patients with advanced gynecological cancers: A prospective study', Gynecologic Oncology, 202, pp. 110 - 117, http://dx.doi.org/10.1016/j.ygyno.2025.09.012

Friedlander ML; Anderson L; Lee YC, 2025, 'Erratum to ‘Controversies in the management of ovarian granulosa cell and Sertoli-Leydig cell tumors’ [International Journal of Gynecological Cancer Volume 35 Issue 3 (2025) 101668] (International Journal of Gynecological Cancer (2025) 35(3), (S1048891X25001938), (10.1016/j.ijgc.2025.101668))', International Journal of Gynecological Cancer, 35, http://dx.doi.org/10.1016/j.ijgc.2025.101953

Harano K; Fossati R; Pardo B; Galli F; Hudson E; Antill Y; Lee C; Rabaglio M; Heitz F; Kolovetsiou-Kreiner V; Lai CH; Biagioli E; Manso L; Nishio S; Allan K; Lee YC; Uggeri S; Redondo A; Nakagawa S; Au E; Lombard J; Gadducci A; Takehara K; Baldini EE; Palaia I; Casanova C; Ardizzoia A; Bologna A; Barretina-Ginesta MP; Colombo N, 2025, 'Phase III double-blind randomized placebo controlled trial of atezolizumab in combination with carboplatin and paclitaxel in women with advanced/recurrent endometrial carcinoma: the Asian cohort of the AtTEnd/ENGOT-EN7 trial', Journal of Gynecologic Oncology, 36, http://dx.doi.org/10.3802/jgo.2025.36.e117

Lim S; Pandher R; Tang K; Chantrill L; Lee YC; Handelsman DJ, 2025, 'Treatment With a Nonaromatizable Androgen for Transgender Man With a Hormone-sensitive Ovarian Cancer', Jcem Case Reports, 3, http://dx.doi.org/10.1210/jcemcr/luaf081

Friedlander ML; Anderson L; Lee YC, 2025, 'Controversies in the management of ovarian granulosa cell and Sertoli-Leydig cell tumors', International Journal of Gynecological Cancer, 35, http://dx.doi.org/10.1016/j.ijgc.2025.101668

Klingberg D; Bae S; Zhou DDX; Sim HW; Cai R; Anazodo A; Grimison P; Lewis C; Lee YC, 2025, 'Association of chemotherapy dose intensity and age with outcomes in patients with Ewing's family sarcoma', Asia Pacific Journal of Clinical Oncology, 21, pp. 87 - 94, http://dx.doi.org/10.1111/ajco.13998

Lee YC; Whitely A; Burling M; Anderson L; Cohen PA; Naidoo M; Richardson G; Perera S; Scott CL; Friedlander M; Brand A; McNally O; Hyde S; Bunting M; Jobling T; Zalcberg J; Rome R, 2025, 'Patterns of care and development of quality indicators in patients with non-epithelial and rare ovarian tumors in Australia: insights from the National Gynae-Oncology Registry', International Journal of Gynecological Cancer, 35, http://dx.doi.org/10.1016/j.ijgc.2024.100052

Giani C; Salawu A; Ljevar S; Denu RA; Napolitano A; Palmerini E; Connolly EA; Ogura K; Wong DD; Scanferla R; Rosenbaum E; Bajpai J; Li ZCC; Bae S; D'Ambrosio L; Bialick S; Wagner AJ; Lee ATJ; Koseła-Paterczyk H; Baldi GG; Brunello A; Lee YC; Loong HH; Boikos S; Campos F; Cicala CM; Maki RG; Hindi N; Figura C; Almohsen SS; Patel S; Jones RL; Ibrahim T; Karim R; Kawai A; Carey-Smith R; Boyle R; Taverna SM; Lazar AJ; Demicco EG; Bovee JVMG; Dei Tos AP; Fletcher C; Baumhoer D; Sbaraglia M; Schaefer IM; Miceli R; Gronchi A; Stacchiotti S, 2025, 'International Multicenter Retrospective Study From the Ultra-rare Sarcoma Working Group on Low-grade Fibromyxoid Sarcoma, Sclerosing Epithelioid Fibrosarcoma, and Hybrid Forms: Outcome of Primary Localized Disease', American Journal of Surgical Pathology, 49, pp. 27 - 34, http://dx.doi.org/10.1097/PAS.0000000000002330

Lee MJ; Lee YC; Bhargava P; Li ZCC; Chen TWW, 2025, 'Maintenance therapy—a potential strategy to prolong the survival of advanced soft tissue sarcoma patients', Therapeutic Advances in Medical Oncology, 17, http://dx.doi.org/10.1177/17588359251377584

Nguyen DT; Davidson T; Maclean F; Dorwal P; Lee YC; Qiu MR, 2025, 'Oligometastatic Renal Ewing Sarcoma With FUS::ERG Fusion: A Case Report And Literature Review', Sage Open Pathology, 18, http://dx.doi.org/10.1177/30502098251336541

Haggstrom L; Lee YC; Ginesta MPB; Jaeger A; Kaiser S; Woopen H; Rhind M; Frenel J-S; Hussain A; Bischof K; Mongillo M; Brodsky AL; Ledermann JA; Ghezelayagh T; Boere IA; Alonso CM; Rosengarten OS; Tucker KM; Friedlander ML, 2025, '1077P How long is long enough? An international GCIG collaboration investigating long term outcomes of exceptional responders with platinum sensitive recurrent ovarian cancer treated with PARP inhibitors', Annals of Oncology, 36, pp. S722 - S723, http://dx.doi.org/10.1016/j.annonc.2025.08.1715

Nicum S; Ledermann JA; Friedlander ML; Mileshkin L; Lee YC; King MT; Mercieca-Bebber R; Smith J; Wilkinson K; Counsell N, 2025, '1089P Telling it as it is: Quality of life outcomes associated with maintenance olaparib and cediranib following a response to chemotherapy in relapsed platinum-sensitive ovarian cancer', Annals of Oncology, 36, pp. S728 - S729, http://dx.doi.org/10.1016/j.annonc.2025.08.1727

Lee J-Y; Oaknin A; Lorusso D; Kim K; Gilbert L; Lee YC; Gao B; Tan D; Oza A; Miller R; O'Malley D; Monk B; Pothuri B; Lu L; Berman C; Borgman A; Naumann W, 2025, 'Efficacy and safety of luveltamab tazevibulin in patients with recurrent platinum-resistant ovarian cancer: Results from the dose-optimization stage of the REFRαME-O1 (GOG-3086, ENGOT-79ov, and APGOT-OV9) phase II/III study', Gynecologic Oncology, 200, pp. 351 - 351, http://dx.doi.org/10.1016/j.ygyno.2025.04.507

Hayes S; Obermair A; Spence R; Mileshkin L; Davis A; Brand A; Barnes E; Collins L; Andrews J; Janda M; Vagenas D; Adams D; Lee YC; Beesley V; Webb P; Friedlander M; O’Neille H; Williams M; Cattley T; Baniahmadi S; Nicklin J; Garrett A; Singh P; Goh J; Shannon C; Perrin L; Nascimento M; Beale P; Alkhateeb A; Sommeijer D; Jones T; Creed M; Rye S; Sandler C; Pumpa K; Stockler M, 2025, 'EXERCISE THERAPY ADDED TO FIRST-LINE CHEMOTHERAPY FOR OVARIAN CANCER: EFFECTS ON PROGRESSION-FREE SURVIVAL AND PHYSICAL WELLBEING IN THE RANDOMISED, PHASE 3 ECHO TRIAL (ANZGOG1304/CTC121)', International Journal of Gynecological Cancer, 35, pp. 102735 - 102735, http://dx.doi.org/10.1016/j.ijgc.2025.102735

Ginesta MPB; Biagioli E; Harano K; Galli F; Hudson E; Antill Y; Roh J-W; Rabaglio M; Marmé F; Piovano E; Leitner K; Madrid LF; Takehara K; Allan K; Lee YC; Zamagni C; Búrdalo BP; Tasca G; Ferrero A; Colombo N, 2025, 'LBA39 Final overall survival (OS) results from the randomized double-blind phase III AtTEnd/ENGOT-EN7 trial evaluating atezolizumab in combination with paclitaxel and carboplatin in women with advanced/recurrent endometrial cancer', Annals of Oncology, 36, pp. S1698 - S1698, http://dx.doi.org/10.1016/j.annonc.2025.09.051

Garg V; Jivraj N; Macanovic B; Pina PS; Grant B; Wang C; Shukla A; Tesfu A; Odujoko O; Madariaga A; Lee YC; Wang L; Veneziani A; Bowering V; Grant RC; Dhani NC; Oza AM; Lheureux S, 2025, 'Multidisciplinary Management of Malignant Bowel Obstruction in Patients with Advanced Gynecological Cancers', The Journal of Emergency Medicine, 76, pp. 144 - 145, http://dx.doi.org/10.1016/j.jemermed.2025.04.040

Mercieca-Bebber R; Barnes EH; Moore KN; Lee YC; Narayan K; Khaw P; Buck M; Fyles A; Brooks S; Lea JS; Stuckey A; Lad TE; Holschneider C; Spirtos NM; Boyd LR; Small W; Monk BJ; Stockler MR; King MT; Mileshkin LR, 2025, 'Patient-reported outcomes (PROs) in locally advanced cervical cancer (LACC): Insights from the OUTBACK trial.', Journal of Clinical Oncology, 43, pp. 5503 - 5503, http://dx.doi.org/10.1200/jco.2025.43.16_suppl.5503

Nahm SH; Kiely BE; O'Connell RL; Lee YC; Davis A; Avall-Lundqvist E; Berek JS; Berton D; Donnellan P; Hilpert F; Joly F; Lanceley A; Ledermann JA; Okamoto A; Oza A; Pignata S; Sehouli J; King MT; Friedlander M; Stockler MR; Roncolato FT; GCIG Symptom Benefit Group , 2025, 'Prognostic significance and accuracy of oncologists' estimates of survival time in recurrent ovarian cancer.', Int J Gynecol Cancer, 35, pp. 100030, http://dx.doi.org/10.1016/j.ijgc.2024.100030

Farrell R; Robledo K; Mcnally O; Chetty N; Harrison M; Ananda S; Simon S; Aberoumand M; Pallimulla S; Alkhateeb A; Burling M; Power J; Kalam S; Stockler M; Lee YC, 2025, 'SAFETY OF HYPERTHERMIC VERSUS NORMOTHERMIC INTRAPERITONEAL CHEMOTHERAPY FOLLOWING INTERVAL CYTOREDUCTIVE SURGERY FOR STAGE III EPITHELIAL OVARIAN CANCER', International Journal of Gynecological Cancer, 35, pp. 102164 - 102164, http://dx.doi.org/10.1016/j.ijgc.2025.102164

Haggstrom L; Lee YC; Scott C; Harter P; Woelber L; Ledermann J; Gourley C; McNeish IA; Amant F; Ray-Coquard I; Leary A; Oza AM; Tinker A; González Martin A; Cecere SC; Pignata S; Colombo N; Yoshida H; Marth C; Rosengarten O; Moore KN; Gómez-García EM; Tan D; Friedlander ML, 2024, 'How long is long enough? An international survey exploring practice variations on the recommended duration of maintenance therapy with PARP inhibitors in patients with platinum sensitive recurrent ovarian cancer and long-term outcomes', International Journal of Gynecological Cancer, 34, pp. 1932 - 1939, http://dx.doi.org/10.1136/ijgc-2024-005976

Lefkovits YR; Heriot N; Sporik A; Perera S; Friedlander M; Dixon C; Cohen PA; Lee YC; Hyde S; Richardson G; Webb P; Rome R; King M; Zalcberg J; Schofield P, 2024, 'Incorporating patient-reported outcome measures (PROMs) into a clinical quality registry (CQR) for ovarian cancer: considerations and challenges', BMC Health Services Research, 24, http://dx.doi.org/10.1186/s12913-024-11042-8

Werner B; Powell E; Duggan J; Cortesi M; Lee YC; Arora V; Athavale R; Dean M; Warton K; Ford CE, 2024, 'Cell-free DNA from ascites identifies clinically relevant variants and tumour evolution in patients with advanced ovarian cancer', Molecular Oncology, 18, pp. 2668 - 2683, http://dx.doi.org/10.1002/1878-0261.13710

Colombo N; Biagioli E; Harano K; Galli F; Hudson E; Antill Y; Choi CH; Rabaglio M; Marmé F; Marth C; Parma G; Fariñas-Madrid L; Nishio S; Allan K; Lee YC; Piovano E; Pardo B; Nakagawa S; McQueen J; Zamagni C; Manso L; Takehara K; Tasca G; Ferrero A; Tognon G; Lissoni AA; Petrella M; Laudani ME; Rulli E; Uggeri S; Barretina Ginesta MP; Zola P; Casanova C; Arcangeli V; Antonuzzo L; Gadducci A; Cosio S; Clamp A; Persic M; McNeish I; Tookman L; Redondo Sanchez A; Baldini E; Palaia I; Benedetti Panici P; Takahashi N; Lombard J; Ardizzoia A; Bologna A; Herrero Ibáñez AM; Musolino A; Márquez Vázquez R; Pietzner K; Braicu E; Heinzelmann-Schwarz VA; Powell M; Yokoyama Y; Baron-Hay S; Abeni C; Martin Lorente C; Cueva JF; Trillsch F; Heitz F; Ataseven B; Petru E; Heubner ML; Sadozye AH; Dubey S; Tazbirkova A; Tiley S; Chrystal K; Kim SW; Fehr M; Scatchard K; Anand A; Taylor A; Watary H; Enomoto T; Yoshihara K; Selva-Nayagam S; Karki B; Harrison M; Wilkinson K; Goh J; Glasgow A; Chantrill L; Lee C; Bertolini A; Narducci F; Bellotti G; Fusco V; Aebi S; Del Grande M; Colombo I; Tokunaga H; Shigeta S; Goss G; Siow ZR; Steer C; Lin H, 2024, 'Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trial', Lancet Oncology, 25, pp. 1135 - 1146, http://dx.doi.org/10.1016/S1470-2045(24)00334-6

Rajadevan N; Flinkier A; Saunders H; Lee YC; Scott C; Khaw P; Allan P; Davies C; Andrews J; Wilson M; Lombard JM; Harrison M; Nesfield H; DeFazio A; Meniawy T; Gorringe KL, 2024, 'Mucinous ovarian carcinoma: A survey of practice in Australia and New Zealand', Australian and New Zealand Journal of Obstetrics and Gynaecology, 64, pp. 319 - 325, http://dx.doi.org/10.1111/ajo.13792

Van Nieuwenhuysen E; Bouberhan S; Papadimitriou K; Arend RC; Lee J-Y; O'Cearbhaill RE; O'Malley DM; You B; Gonzalez Martin A; Michels J; Mileshkin LR; Lee YC; Miller R; Yoo S-Y; Peterman MJ; Schmidt T; Knorr D; Lowy I; Uldrick TS; Miller E, 2024, 'A phase 1/2 study of ubamatamab (REGN4018), a MUC16×CD3 bispecific antibody, administered alone or in combination with cemiplimab (anti–PD-1) in patients with recurrent ovarian cancer or MUC16+ endometrial cancer.', Journal of Clinical Oncology, 42, pp. TPS5632 - TPS5632, http://dx.doi.org/10.1200/jco.2024.42.16_suppl.tps5632

Oaknin A; Lee J-Y; Cibula D; Lee YC; Schilder RJ; Auranen A; Gao B; Tan DSP; Oza AM; Miller R; Salutari V; Tasca G; O'Malley DM; Monk BJ; Pothuri B; Lu L; Berman C; Borgman A; Naumann RW, 2024, 'Efficacy and safety of luveltamab tazevibulin vs investigator’s choice of chemotherapy in patients with recurrent platinum-resistant ovarian cancer (PROC) expressing folate receptor alpha (FRα): The REFRaME-01 (GOG-3086, ENGOT-79ov, and APGOT-OV9) phase 2/3 study.', Journal of Clinical Oncology, 42, pp. TPS5637 - TPS5637, http://dx.doi.org/10.1200/jco.2024.42.16_suppl.tps5637

Roncolato F; King MT; O'Connell RL; Lee YC; Joly F; Hilpert F; Lanceley A; Yoshida Y; Bryce J; Donnellan P; Oza A; Avall-Lundqvist E; Berek JS; Ledermann JA; Berton D; Sehouli J; Kaminsky MC; Stockler MR; Friedlander M, 2024, 'Hidden in plain sight – Survival consequences of baseline symptom burden in women with recurrent ovarian cancer', Gynecologic Oncology, 185, pp. 128 - 137, http://dx.doi.org/10.1016/j.ygyno.2024.02.025

Naidoo M; Scott CL; McNally O; Rome R; Perera S; Lee YC; Whitely A; Burling M; Anderson L; Cohen P; Richardson GE; Friedlander M; Brand A; Hyde S; Bunting M; Jobling T; Zalcberg JR, 2024, 'Overall survival and patterns of care for women with rare ovarian cancers: A prospective study from the Australian National Gynae-Oncology Registry (NGOR).', Journal of Clinical Oncology, 42, pp. e17554 - e17554, http://dx.doi.org/10.1200/jco.2024.42.16_suppl.e17554

Lee YC; Castellano T; Myers TKN; Barnes EH; Chase DM; McCormick C; Diamante K; Shannon CM; Huh WK; Lea JS; Walker JL; Small W; Miller K; Govindarajulu G; Monk BJ; Stockler MR; Moore KN; Mileshkin LR; Bae-Jump VL, 2024, 'Racial disparities and survival outcome of patients with locally advanced cervix cancer in the international randomised phase 3 OUTBACK trial (ANZGOG 0902, RTOG 1174, NRG 0274).', Journal of Clinical Oncology, 42, pp. 1594 - 1594, http://dx.doi.org/10.1200/jco.2024.42.16_suppl.1594

Garg V; Alqaisi H; Soberanis Pina P; Veneziani A; Pannu AK; Grant B; Braik D; Wang C; Shukla A; Tesfu A; Odujoko O; Madariaga A; Lee YC; Wang L; Jivraj N; Bowering V; Grant RC; Dhani NC; Oza AM; Lheureux S, 2024, 'Risk-stratified multidisciplinary ambulatory management of malignant bowel obstruction (MAMBO) program in women with advanced gynaecological cancers: A prospective study.', Journal of Clinical Oncology, 42, pp. 12076 - 12076, http://dx.doi.org/10.1200/jco.2024.42.16_suppl.12076

Symons R; Heath F; Duggan J; Bui KT; Byun L; Friedlander M; Lee YC, 2024, 'Rates of paclitaxel hypersensitivity reactions using a modified Markman's infusion protocol as primary prophylaxis.', Support Care Cancer, 32, pp. 292, http://dx.doi.org/10.1007/s00520-024-08460-z

Grisham R; Monk BJ; Van Nieuwenhuysen E; Moore KN; Fabbro M; O'Malley DM; Oaknin A; Thaker P; Oza AM; Colombo N; Gershenson D; Aghajanian CA; Choi CH; Lee YC; Mirza MR; Coleman RL; Cobb L; Harter P; Lustgarten S; Youssoufian H; Banerjee S, 2024, 'GOG-3097/ENGOT-ov81/GTG-UK/RAMP 301: A phase 3, randomized trial evaluating avutometinib plus defactinib compared with investigator's choice of treatment in patients with recurrent low grade serous ovarian cancer', International Journal of Gynecological Cancer, http://dx.doi.org/10.1136/ijgc-2024-005919

Werner B; Powell E; Duggan J; Cortesi M; Lee YC; Arora V; Athavale R; Dean M; Warton K; Ford C, 2024, 'Use of cell-free DNA from ascites to identify variants and tumour evolution in a cohort of patients with advanced ovarian cancer.', Journal of Clinical Oncology, 42, pp. 5547 - 5547, http://dx.doi.org/10.1200/JCO.2024.42.16_suppl.5547

Haggstrom LR; Lee YC; Scott CL; Ledermann JA; Gourley C; McNeish I; Amant F; Ray-Coquard IL; Leary A; Oza AM; Tinker A; Gonzalez-Martin A; Cecere SC; Colombo N; Yoshida H; Marth C; Gomez Garcia EM; Tan DS; Moore KN; Friedlander ML, 2024, 'How long is long enough? An international survey exploring practice variations on the recommended duration of maintenance therapy with PARP inhibitors in platinum sensitive recurrent ovarian cancer and long-term outcomes', ANNALS OF ONCOLOGY, 35, pp. S578 - S579, http://dx.doi.org/10.1016/j.annonc.2024.08.825

Nicum S; Ledermann JA; Mileshkin L; Jayson GC; Gourley C; Michael A; Lord R; Mackay H; Hall M; Tookman L; Banerjee S; Harnett P; Macdonald I; Lee YC; Elyashiv O; Wilkinson K; Farrelly L; Counsell N, 2024, 'ICON9: International phase III randomized study to evaluate the efficacy of maintenance therapy with olaparib and cediranib or olaparib alone in patients with relapsed platinum-sensitive ovarian cancer following a response to platinum-based chemotherapy', ANNALS OF ONCOLOGY, 35, pp. 1225 - 1226, http://dx.doi.org/10.1016/j.annonc.2024.08.2272

Scott CL; Friedlander ML; Francis K; Kartikasari AER; Diamante K; Bound N; Davies C; O'Connell R; Lee YC; Lombard J; Baron-Hay SE; Antill Y; Shannon C; Selva-Nayagam S; Beale PJ; Shield-Artin K; Wakefield M; Vandenberg C; Plebanski M; Lee CK, 2024, 'SOLACE2: A phase II randomized trial of olaparib (O) and durvalumab (D) with or without low dose cyclophosphamide (LDCy) in platinum-sensitive recurrent ovarian cancer (PSROC)', ANNALS OF ONCOLOGY, 35, pp. S566 - S567, http://dx.doi.org/10.1016/j.annonc.2024.08.808

Gonzalez-Ochoa E; Milosevic M; Corr B; Abbruzzese JL; Girda E; Miller RW; Croke J; Mackay H; Lee YC; Bowering V; Ramsahai J; Wang L; D'Souza A; Kunos CA; Oza AM; Lheureux S, 2023, 'A phase i study of the Wee1 kinase inhibitor adavosertib (AZD1775) in combination with chemoradiation in cervical, upper vaginal, and uterine cancers', International Journal of Gynecological Cancer, 33, pp. 1208 - 1214, http://dx.doi.org/10.1136/ijgc-2023-004491

Mileshkin LR; Narayan K; Gaffney DK; Barnes EH; Lee YC; Monk BJ; Stockler MR, 2023, 'Adjuvant chemotherapy for locally advanced cervical cancer – Authors’ reply', Lancet Oncology, 24, pp. e290, http://dx.doi.org/10.1016/S1470-2045(23)00294-2

Lindemann K; Liland H; Donner MS; Brew S; Lee YC; Vistad I; Berge Nilsen E; Lombard JM; Mirza MR; Madsen K; Hansson AM; Andrews J; Campbell R; Davis AJ, 2023, 'GCIG SB-001/NSGO-CTU-PEACE/ANZGOG 1923/2020: Palliation in gynae-oncology—Patients' expectations and assessment of care.', Journal of Clinical Oncology, 41, pp. TPS5635 - TPS5635, http://dx.doi.org/10.1200/jco.2023.41.16_suppl.tps5635

Buchanan DD; Mahmood K; Georgeson P; Walker R; Robledo K; Cummins MM; Spurdle AB; Smith DS; Joo E; Clendenning M; Como J; Preston S; Yip S; Andrews J; Kok PS; Lee YC; Stockler MR; Mileshkin LR; Antill YC, 2023, 'The impact of cause of mismatch repair deficiency and other molecular markers on clinical outcomes with the use of durvalumab in advanced endometrial cancer in the phase 2 PHAEDRA trial (ANZGOG1601).', Journal of Clinical Oncology, 41, pp. 5604 - 5604, http://dx.doi.org/10.1200/jco.2023.41.16_suppl.5604

Mileshkin LR; Moore KN; Barnes EH; Gebski V; Narayan K; King MT; Bradshaw N; Lee YC; Diamante K; Fyles AW; Small W; Gaffney DK; Khaw P; Brooks S; Thompson JS; Huh WK; Mathews CA; Buck M; Suder A; Lad TE; Barani IJ; Holschneider CH; Van Dyk S; Quinn M; Rischin D; Monk BJ; Stockler MR, 2023, 'Adjuvant chemotherapy following chemoradiotherapy as primary treatment for locally advanced cervical cancer versus chemoradiotherapy alone (OUTBACK): an international, open-label, randomised, phase 3 trial', Lancet Oncology, 24, pp. 468 - 482, http://dx.doi.org/10.1016/S1470-2045(23)00147-X

Pitiyarachchi O; Lee YC; Sim HW; Srirangan S; Mapagu C; Kirk J; Harnett PR; Balleine RL; Bowtell DDL; Samimi G; Brand AH; Marsh DJ; Beale P; Anderson L; Bouantoun N; Provan P; Ramus SJ; DeFazio A; Friedlander M, 2023, 'Older age should not be a barrier to testing for somatic variants in homologous recombination DNA repair-related genes in patients with high-grade serous ovarian carcinoma', Translational Oncology, 31, http://dx.doi.org/10.1016/j.tranon.2023.101638

Hayes S; Obermair A; Mileshkin L; Davis A; Gordon LG; Eakin E; Janda M; Beesley VL; Barnes EH; Spence RR; Sandler C; Jones T; Vagenas D; Webb P; Andrews J; Brand A; Lee YC; Friedlander M; Pumpa K; O'Neille H; Williams M; Stockler M, 2023, 'Exercise during CHemotherapy for Ovarian cancer (ECHO) trial: Design and implementation of a randomised controlled trial', BMJ Open, 13, http://dx.doi.org/10.1136/bmjopen-2022-067925

Cohen PA; Webb PM; King M; Obermair A; Gebski V; Butow P; Morton R; Lawson W; Yates P; Campbell R; Meniawy T; McMullen M; Dean A; Goh J; McNally O; Mileshkin L; Beale P; Beach R; Hill J; Dixon C; Hegarty S; Codde J; Ives A; Lee YC; Brand A; Mellon A; Bilic S; Black I; Jeffares S; Friedlander M, 2023, 'Getting the MOST out of follow-up: A randomized controlled trial comparing 3 monthly nurse led follow-up via telehealth, including monitoring CA125 and patient reported outcomes using the MOST (Measure of Ovarian Symptoms and Treatment concerns) with routine clinic based or telehealth follow-up, after completion of first line chemotherapy in patients with epithelial ovarian cancer', International Journal of Gynecological Cancer, http://dx.doi.org/10.1136/ijgc-2021-002999

Jivraj N; Lee YC; Tinker L; Bowering V; Ferguson SE; Croke J; Karakasis K; Chawla T; Lau J; Ng P; Dhar P; Shlomovitz E; Buchanan S; Dhani N; Oza AM; Stuart-Mcewan T; Lheureux S, 2023, 'Management of Malignant Bowel Obstruction: An Innovative Proactive Outpatient Nurse-Led Model of Care for Patients With Advanced Gynecologic Cancer', Journal of Nursing Care Quality, 38, pp. 69 - 75, http://dx.doi.org/10.1097/NCQ.0000000000000661

Smith D; Robledo KP; Yip S; Cummins MM; Kok PS; Lee YC; Friedlander M; Baron-Hay S; Shannon C; Coward J; Beale P; Goss G; Meniawy T; Lombard J; Spurdle AB; Andrews J; Stockler MR; Mileshkin L; Antill Y, 2023, 'Results of PD-L1 Analysis of Women Treated with Durvalumab in Advanced Endometrial Carcinoma (PHAEDRA)', Cancers, 15, http://dx.doi.org/10.3390/cancers15010254

Friedlander M; Lee YC; Tew WP, 2023, 'Managing Adverse Effects Associated With Poly (ADP-ribose) Polymerase Inhibitors in Ovarian Cancer: A Synthesis of Clinical Trial and Real-World Data.', Am Soc Clin Oncol Educ Book, 43, pp. e390876, http://dx.doi.org/10.1200/EDBK_390876

Campbell R; King MT; Stockler MR; Lee YC; Roncolato FT; Friedlander ML, 2023, 'Patient-Reported Outcomes in Ovarian Cancer: Facilitating and Enhancing the Reporting of Symptoms, Adverse Events, and Subjective Benefit of Treatment in Clinical Trials and Clinical Practice', PATIENT-RELATED OUTCOME MEASURES, 14, pp. 111 - 126, http://dx.doi.org/10.2147/PROM.S297301

Back to profile page